ReviewBMC anesthesiology2026
Safe and successful use of remimazolam for gastrointestinal endoscopy in a patient with propofol-induced seizure-like phenomena: a case report and literature review.
Review in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPropofol is widely used for sedation during gastrointestinal endoscopy and is generally considered safe for patients with epilepsy. However, a tiny subset of patients may experience seizure-like phenomena (SLP) following its administration. CASE DESCRIPTION: We present a case of a 28-year-old woman who experienced SLP on two separate occasions after propofol administration during gastroscopy and colonoscopy. The patient developed generalized tonic-clonic seizures after receiving propofol, requiring emergency management with midazolam. All preoperative examinations, including electroencephalogram and head CT, showed no abnormalities. On the third endoscopic procedure, remimazolam was used instead of propofol, resulting in the successful completion of the procedure without any adverse events. COMMENTS/REVIEW: Propofol exhibits complex neuropharmacology capable of inducing paradoxical excitation through multiple interconnected mechanisms. Evidence points to transient neural instability during rapid concentration shifts in induction and emergence phases, altered brain network dynamics, individual genetic susceptibility in calcium homeostasis, and potential glycine receptor antagonism as contributing factors to SLP. In this context, remimazolam presents a mechanistically rational alternative due to its selective GABAergic activity without paradoxical excitation, inherent anticonvulsant properties, and enhanced safety profile including flumazenil reversibility. This review consolidates current evidence establishing remimazolam as a safe and effective sedative alternative for patients with documented propofol-induced SLP
conclusionsThis case highlights the potential for propofol to induce SLP even in patients without underlying neurological disorders. Remimazolam appears to be a safe and effective alternative for patients who experience propofol-related SLP during procedural sedation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.